Erratum: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk (Lancet (March 1, 2003) 361 (717-725) PII: S0140-6736(03)12655-4 and DOI: 10.1016/S0140-6736(03)12655-4);Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk

Lancet

Volumn 361, Issue 9359, 2003, Pages 717-725

  Murray, Christopher J L ^a   Lauer, Jeremy A ^a   Hutubessy, Raymond C W ^a   Niessen, Louis ^b   Tomijima, Niels ^a   Rodgers, Anthony ^c   Lawes, Carlene M M ^c   Evans, David B ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 0037334224     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66908-5     Document Type: Erratum

References (48)

1. The World Health Report: reducing risks, promoting healthy life. 2002;2002 WHO, Geneva.
2. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J.L. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 360:2002;1347-1360.
3. Murray C.J.L., Lopez A.D. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1st edn:1996;Harvard University Press, Cambridge, MA.
4. Puska P. Development of public policy on the prevention and control of elevated blood cholesterol. Cardiovasc Risk Factors. 6:1996;203-210.
5. World Health Organization. Innovative care for chronic conditions: building blocks for action. Geneva: WHO, document No WHO/MNC/CCH/02.01: 2002.
6. Johns B, Baltussen R, Hutubessy RCW. Programme costs in the economic evaluation of health interventions. (in press).
7. Adam T, Evans DB, Koopmanschap MA. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care(in press).
8. Baltussen RM, Adam T, Tan Torres T, et al. Generalized cost-effectiveness analysis: a guide. Geneva: WHO, Global Programme on Evidence for Health Policy: 2002. Available at: http://www.who.int/evidence/cea.
9. Adam T, Evans DB, Murray CJL. Econometric estimation of country-specific hospital costs. (in press).
10. Murray C.J., Evans D.B., Acharya A., Baltussen R.M. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 9:2000;235-251.
11. Hutubessy R.C., Baltussen R.M., Evans D.B., Barendregt J.J., Murray C.J. Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ. 10:2001;473-477.
12. Hutubessy R.C.W., Baltussen R.M.P.M., Tan Torres-Edejer T., Evans D.B. Generalised cost-effectiveness analysis: an aid to decision making in health. Appl Health Econ Health Policy. 1:2002;89-95.
13. Baltussen R.M., Hutubessy R.C., Evans D.B., Murray C.J. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care. 18:2002;112-119.
14. Martin I. Implementation of WHO/ISH Guidelines: role and activities of WHO. Clin Exp Hypertens. 21:1999;659-669.
15. Law M.R., Wald N.J. Risk factor thresholds: their existence under scrutiny. BMJ. 324:2002;1570-1576.
16. Cooper R.S., Rotimi C.N., Kaufman J.S., Muna W.F., Mensah G.A. Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. BMJ. 316:1998;614-617.
17. Marshall T., Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ. 325:2002;197-199.
18. Ebrahim S., Smith G.D. Exporting failure? Coronary heart disease and stroke in developing countries. Int J Epidemiol. 30:2001;201-205.
19. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. Cardiovascular disease risk profiles. Am Heart J. 121:1991;293-298.
20. Jackson R., Barham P., Bills J., et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 307:1993;107-110.
21. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med. 152:1992;56-64.
22. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 352:1998;1801-1807.
23. Jee S.H., Suh I., Kim I.S., Appel L.J. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. JAMA. 282:1999;2149-2155.
24. Lawes C, Vander Hoorn S, Rodgers A. Blood pressure and burden of disease. In: Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO (in press).
25. Lawes C, Vander Hoorn S, Law MR, MacMahon S, Rodgers A. Global disease burden attributable to cholesterol. In: Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO (in press).
26. Lambert J.D. Numerical methods for ordinary differential systems: the initial value problem. 1991;Wiley, Chichester.
27. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 308:1994;367-372.
28. Age-specfic relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 360:2002;1903-1913.
29. Jamison D.T., Mosley W.H., Measham A.R., Bobadilla J.L. Disease control priorities in developing countries. 1993;Oxford University Press, New York.
30. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York.
31. WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO, 2001.
32. Fortmann S.P., Varady A.N. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: the Stanford Five-City Project. Am J Epidemiol. 152:2000;316-323.
33. Vartiainen E., Puska P., Jousilahti P., Korhonen H.J. Cardiovascular diseases and risk factors in Finland. Prev Med. 29:1999;S124-S129.
34. Sellers D.E., Crawford S.L., Bullock K., McKinlay J.B. Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Soc Sci Med. 44:1997;1325-1339.
35. Hooper L., Bartlett C., Davey S.G., Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 325:2002;628.
36. Rodgers A., Neal B. Less salt does not necessarily mean less taste. Lancet. 353:1999;1332.
37. Law MR, Wald NJ, Morris JK, Jordon RE. Blood pressure lowering drugs: analysis of 354 randomised trials to assess the value of low dose combination therapy. BMJ(in press).
38. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effecct of pravastatin on coronary disease events in subgroups defined by coronary risk factors-the prospective pravastatin pooling project. Circulation. 102:2000;1893-1900.
39. Richard F., Fromentin-David I., Ricolfi F., et al. The angiotensin I converting enzyme gene as a susceptibility factor for dementia. Neurology. 56:2001;1593-1595.
40. Collins R., Armitage J., Parish S., Sleight P., Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
41. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide on dementia and severe cognitive decline in patients with cerebrovascular disease. Arch Intern Med (in press).
42. Forette F., Seux M.L., Staessen J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 352:1998;1347-1351.
43. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 356:2000;1955-1964.
44. Marmot M., Shipley M., Brunner E., Hemingway H. Relative contribution of early life and adult socioeconomic factors to adult morbidity in the Whitehall II study. J Epidemiol Community Health. 55:2001;301-307.
45. Haynes R.B., McKibbon K.A., Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 348:1996;383-386.
46. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;765-774.
47. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 346:1995;1647-1653.
48. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia Pacific region. J Hypertens(in press).